Summaries for patients. Cost-effectiveness of pneumococcal vaccine for people 50 through 64 years of age.
D000368:Aged; D003198:Computer Simulation; D003362:Cost-Benefit Analysis; D006801:Humans; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000517:prevention & control*; D022242:Pneumococcal Vaccines / Q000191:economics*; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000191:economics* / Q000706:statistics & numerical data
D022242:Pneumococcal Vaccines